RTT

Rett syndrome - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report 2023 To 2033

Retrieved on: 
Tuesday, April 9, 2024
Knowledge, Neurology, Acadia Pharmaceuticals, Pediatrics, CDKL5, Communication, RTT, Patient, FOXG1, Research, Disorder, Competitive landscape, Rett syndrome, Drug development, USFDA

HARTFORD, Conn., April 9, 2024 /PRNewswire/ -- Thelansis Knowledge Partners, specialized in pharmaceutical and biopharmaceutical business research and consulting Company that provides data driven research and consulting support released highly valued Market Outlook Report Title: Rett syndrome - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report 2023 To 2033

Key Points: 
  • HARTFORD, Conn., April 9, 2024 /PRNewswire/ -- Thelansis Knowledge Partners, specialized in pharmaceutical and biopharmaceutical business research and consulting Company that provides data driven research and consulting support released highly valued Market Outlook Report Title: Rett syndrome - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report 2023 To 2033
    Rett Syndrome (RTT) is an orphan neurodevelopmental disorder for which no cure exists.
  • The condition is clinically heterogenous; key patient types include typical or classical RTT and atypical RTT.
  • Although the disorder is rare, it causes life-long impairment and severe symptoms requiring treatments such as antiepileptics and supportive therapies.
  • Only one drug is USFDA approved for the treatment of RTT: Daybue (trofinetide), which is marketed by Acadia Pharmaceuticals.

Rett syndrome - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report 2023 To 2033

Retrieved on: 
Tuesday, April 9, 2024
Knowledge, Neurology, Acadia Pharmaceuticals, Pediatrics, CDKL5, Communication, RTT, Patient, FOXG1, Research, Disorder, Competitive landscape, Rett syndrome, Drug development, USFDA

HARTFORD, Conn., April 9, 2024 /PRNewswire/ -- Thelansis Knowledge Partners, specialized in pharmaceutical and biopharmaceutical business research and consulting Company that provides data driven research and consulting support released highly valued Market Outlook Report Title: Rett syndrome - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report 2023 To 2033

Key Points: 
  • HARTFORD, Conn., April 9, 2024 /PRNewswire/ -- Thelansis Knowledge Partners, specialized in pharmaceutical and biopharmaceutical business research and consulting Company that provides data driven research and consulting support released highly valued Market Outlook Report Title: Rett syndrome - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report 2023 To 2033
    Rett Syndrome (RTT) is an orphan neurodevelopmental disorder for which no cure exists.
  • The condition is clinically heterogenous; key patient types include typical or classical RTT and atypical RTT.
  • Although the disorder is rare, it causes life-long impairment and severe symptoms requiring treatments such as antiepileptics and supportive therapies.
  • Only one drug is USFDA approved for the treatment of RTT: Daybue (trofinetide), which is marketed by Acadia Pharmaceuticals.

Kyocera Adds Wi-Fi Calling to DuraSport 5G for Priority Service Customers Offering First Responders Rugged Reliability

Retrieved on: 
Tuesday, February 20, 2024
Consumer Electronics, Carriers and Services, Technology, Public Relations, Investor Relations, Wearables, Mobile Technology, Communications, Telecommunications, Audio, Video, Internet, Mobile, Wireless, Hardware, Emergency, Human voice, Sand, RTT, TAA, Multimedia, Shock, HD, U.S. Cellular, IPX8, QOS, Vibration, Public sector, Immersion, Smartphone, Element, Water, GPS, Police, Single-camera setup, Lithium

Kyocera has added Wi-Fi calling connectivity for UScellular ’s Priority Services on DuraSport 5G , the company announced today.

Key Points: 
  • Kyocera has added Wi-Fi calling connectivity for UScellular ’s Priority Services on DuraSport 5G , the company announced today.
  • The rugged MIL-STD-810H 5G Android 13 device has supported Priority Services since its original launch and now adds Wi-Fi calling support to enhance rugged reliability for police, fire, and other first responders.
  • Priority Services ensures that first responders’ calls receive priority support on networks to save precious time in emergencies.
  • View the full release here: https://www.businesswire.com/news/home/20240220798134/en/
    Wi-Fi calling added to Kyocera DuraSport 5G available with Uscellular.

MEC to X Solution Helps 5GtoB Achieve Closed-Loop Business Operations

Retrieved on: 
Monday, February 26, 2024
Cloud, RTT, Mobile, GSMA, Internet of things, Growth, Dou, Redcap, University, CTM, City, Huawei, University of Macau, LAN, MEC, Mobile phone

Against this backdrop, Huawei proposes the MEC to X solution powered by the Kite-Like Solution to construct local-area, wide-area, and cross-domain private networks.

Key Points: 
  • Against this backdrop, Huawei proposes the MEC to X solution powered by the Kite-Like Solution to construct local-area, wide-area, and cross-domain private networks.
  • This solution is able to shore up a variety of industries, lead their digital transformation, and help 5GtoB achieve business success.
  • The Kite-Like Solution, which upholds the concept of public network integrated non-public network (PNI-NPN), has been widely deployed for more than 40 industries in over 200 cities.
  • This solution helps build the nation's first 5G industry private network with the widest coverage and largest application.

Anavex Life Sciences Reports Fiscal 2024 First Quarter Financial Results and Provides Business Update

Retrieved on: 
Wednesday, February 7, 2024
Clinical trial, Marketing authorisation, FDA, Expanded access, Genome, Frontotemporal dementia, Safety, Food, OLE, Real, CNS, Medicine, Publication, Committee, RTT, Rett syndrome, Patent, Marketing, CHMP, European, Human, DSM-IV codes, Research, Patient, Drug development, Pharmacokinetics, Pharmacology, Central nervous system, Webcast, Conference call, Doctor of Philosophy, Treatment, EDGAR, MECP2, Union, Therapy, EMA, RWE, Alzheimer's disease, European Medicines Agency, Neurodevelopmental disorder, Bank statement, Conference, Pharmaceutical industry

NEW YORK, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome, schizophrenia and other central nervous system (CNS) diseases, today reported financial results for its fiscal quarter ended December 31, 2023.

Key Points: 
  • The Marketing Authorisation would allow direct market access throughout the European Union for oral blarcamesine for the treatment of Alzheimer’s disease.
  • We intend to further assess the results and discuss with the regulatory authorities next steps.
  • General and administrative expenses for the quarter of $2.6 million compared to $3.3 million for the comparable first quarter of fiscal 2023.
  • Research and development expenses for the fourth quarter of $8.7 million compared to $12.1 million for the comparable first quarter of fiscal 2023.

With $200,000 Grant from Medica, RealTime Talent Seeks to Address Long Term Care Workforce Labor Shortages

Retrieved on: 
Wednesday, January 17, 2024
Human Resources, Hospitals, Professional Services, Philanthropy, Managed Care, Health, General Health, Other Philanthropy, Foundation, Service, Community, Student, Nursing care plan, Research, American Securities, TPM, RTT, International Institute of Minnesota, Workforce, Human, Nursing

RealTime Talent (RTT) was awarded a $200,000 grant from Medica to reduce certified nursing assistant shortages in long term care and older adult service facilities by implementing a newly designed training approach that will increase talent attraction and retention in this segment of health care.

Key Points: 
  • RealTime Talent (RTT) was awarded a $200,000 grant from Medica to reduce certified nursing assistant shortages in long term care and older adult service facilities by implementing a newly designed training approach that will increase talent attraction and retention in this segment of health care.
  • RTT is hosting the only Long Term Care Talent Pipeline Management® (TPM) Collaborative in the state.
  • TPM helps employers improve their return on investment in various recruiting and retention processes by addressing talent issues using research and data-informed insights.
  • The participating long term care and older adult services employers need to hire nearly 3,200 certified nursing assistants (CNAs) in the 2022-2024 timeframe.

OSI Systems Receives $4 Million Order to Provide Security Inspection Systems for Air Cargo Screening

Retrieved on: 
Thursday, January 11, 2024
Construction & Property, Contracts, Air, Engineering, Transport, Aerospace, Building Systems, Manufacturing, Logistics, Supply Chain Management, Defense, RTT, Partnership, OSI Systems, Security, OSI, Rapiscan

OSI Systems, Inc .

Key Points: 
  • OSI Systems, Inc .
  • (the "Company" or "OSI Systems") (NASDAQ: OSIS) today announced that its Security division received an order from a leading global air cargo logistics provider for approximately $4 million to provide advanced security inspection systems including the Rapiscan® RTT®110 CT-based explosive detection system, the Rapiscan Orion® 927DX and 935DX for large package screening, and the Rapiscan Orion 920CX for small parcel screening, among others.
  • OSI Systems’ Chairman and CEO, Deepak Chopra, commented, "We are privileged to enhance our robust partnership with this long-standing customer and support its premier global air cargo hub.
  • These systems are expected to be integrated into a high-speed parcel screening environment, optimizing the capabilities of the RTT and Orion platforms.”

Anavex Life Sciences Provides an Update on Rett Syndrome Program

Retrieved on: 
Tuesday, January 2, 2024
DSM-IV codes, Lethargy, Șaeș, AVATAR, Rett syndrome, Caregiver, Microsoft Access, Research, Fragile X syndrome, Marketing, FDA, EMA, Data analysis, Disease, Somnolence, MD, Doctor of Philosophy, Clinical trial, Seizure, Orphan drug, Clinical Global Impression, European Medicines Agency, CHMP, Expanded access, Anxiety, Committee, Safety, Patient, Placebo, Real, RTT, Therapy, OLE, Fast Track, RWE, Pharmaceutical industry

NEW YORK, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders today reported topline results from the randomized, double-blind, placebo-controlled, Phase 2/3 EXCELLENCE clinical trial, which evaluated the clinical efficacy, safety, and tolerability of 30 mg ANAVEX®2-73 in 92 pediatric patients with Rett syndrome (RTT) between the ages of 5 through 17 years. Participants were randomized 2:1 (ANAVEX®2-73 [62 patients] to placebo [30 patients]) for 12 weeks, followed by a week 16 safety visit. As well, Anavex reported positive Real World Evidence (RWE) feedback from Rett syndrome patients under Compassionate Use Authorization.

Key Points: 
  • As well, Anavex reported positive Real World Evidence (RWE) feedback from Rett syndrome patients under Compassionate Use Authorization.
  • After 12 weeks, the study showed improvement on the key co-primary endpoint Rett Syndrome Behaviour Questionnaire (RSBQ), which is a detailed 45-item questionnaire for assessing multiple Rett syndrome characteristics by the patients’ caregivers.
  • As of today, some patients with Rett syndrome have been on ANAVEX®2-73-treatment for over 4 years, combined OLE and Compassionate Use Program.
  • In addition to Rett syndrome, Anavex is evaluating ANAVEX®2-73 in other neurodevelopmental disorders, including Fragile X syndrome, and in neurodegenerative disorders like Parkinson’s disease.

Telchemy extends Teams support in VQmon VoIP and Video QoE Analytics

Retrieved on: 
Monday, December 11, 2023
Technology, Telecommunications, Professional Services, Software, Audio, Video, Networks, Data Analytics, Data Management, IOT (Internet of Things), VoIP, T.38, IETF, Telchemy, RTT, WebRTC, H.266/VVC, Human voice, IP, AVC, AES67, DPI, KPI-driven code analysis, Algorithm, Scalable Video Coding, Zoom, DNS, Real-time, QUIC, Fax, DASH, Microsoft Teams, TCP, Satin, ICMP, Speech, SMPTE, AV1, H.265/HEVC, IPTV, Voice over IP, DANTE, UDP, Microsoft, Human, Quality of experience, Mobile phone, Videotelephony, TEAMS

VQmon 5.4, the latest version of Telchemy’s market-leading embedded analytics software, is now available with enhanced Microsoft Teams analytics.

Key Points: 
  • VQmon 5.4, the latest version of Telchemy’s market-leading embedded analytics software, is now available with enhanced Microsoft Teams analytics.
  • VQmon supports Voice over IP (VoIP), Videoconferencing, Video Streaming, Broadcast Audio/Video, Data, Real Time Text (RTT) and Fax over IP (FoIP) applications.
  • VQmon 5.4 adds support for Microsoft's Satin audio codec and the Scalable Video Coding codec used in Teams, to the H.264/AVC, H.265/HEVC, H.266/VVC, AV1 and extensive range of speech, audio and video codecs already supported.
  • Reporting accurate diagnostics, performance metrics and KPIs, including QoE, MOS and R-factor scores, VQmon is the most widely accepted analytics library for real-time application performance analysis.

Kyocera Launches Unlocked DuraSport 5G with UScellular: Rugged Reliability to Help You Work Hard, Play Harder, in Time for Holidays

Retrieved on: 
Tuesday, November 21, 2023
Data Management, Carriers and Services, Technology, Telecommunications, Apps, Applications, Software, Networks, Internet, Mobile, Wireless, 5G, Hardware, RTT, Human voice, GPS, U.S. Cellular, Shock, HD, Vibration, Smartphone, Immersion, Multimedia, Element, Multi, IPX8, Ecosystem, Map, Music, Credit, QOS, TAA, Water, Skiing, Altitude, Tax, PTT, Lithium, Sand, Parenting, Mobile phone, Wi-Fi, Kyocera, Bluetooth

Kyocera and UScellular launched the unlocked version of DuraSport 5G , a rugged MIL-STD-810H 5G Android 13 device in a sleek, slim form factor.

Key Points: 
  • Kyocera and UScellular launched the unlocked version of DuraSport 5G , a rugged MIL-STD-810H 5G Android 13 device in a sleek, slim form factor.
  • Engineered to withstand drops, dirt, water immersion and the elements, Kyocera DuraSport 5G can be washed and sanitized to eliminate grit and grime from outdoor adventures or busy day-to-day activities.
  • Engineered to withstand drops, dirt, water immersion and the elements, Kyocera DuraSport 5G can be washed and sanitized to eliminate grit and grime from outdoor adventures or busy day-to-day activities.
  • (Photo: Business Wire)
    DuraSport 5G’s durable, lightweight design (6.5 ounces/185 grams) is ideal for outdoor activities or the daily adventures of parenting.